The company reported a consolidated net profit of ₹57 crore for the June quarter, compared with ₹45 crore in the corresponding period last year, marking a 25.8% year-on-year increase.
Revenue from operations increased 16.6% to ₹450 crore from ₹386 crore a year earlier.
Operating performance also improved, with EBITDA rising 22% year-on-year to ₹217 crore.
EBITDA margin expanded to 48.3% from 46.1% in the year-ago period.
The faster growth in EBITDA compared with revenue indicates that Metropolis benefited from operating leverage, with higher volumes helping the company improve profitability without a similar increase in costs.
Patient and test volumes continue to expand
Metropolis said patient volumes increased 10% year-on-year, while test volumes rose 11% during the quarter.
The company attributed the growth to sustained demand, deeper market penetration and the continued shift towards organised diagnostic chains.
The diagnostics sector has been gradually moving away from fragmented local laboratories towards branded chains, as consumers increasingly prioritise reliability, quality standards and faster digital access to reports.
The company’s business-to-consumer (B2C) segment remained a key growth driver, with revenue increasing 18% during the quarter.
Metropolis said B2C growth was supported by brand strength, targeted marketing initiatives and higher digital engagement.
Its business-to-business (B2B) segment also performed well, with revenue rising 15%, helped by expansion of its clinician and institutional network.
While B2C businesses typically provide stronger brand visibility and direct customer relationships, B2B partnerships with doctors, hospitals and institutions provide steady volumes and wider reach.
Premium diagnostics and wellness offerings gain traction
Metropolis continued to see strong growth in its specialised diagnostic offerings.
Revenue from TruHealth increased 22% year-on-year to ₹81 crore, contributing around 18% of total revenue.
Specialty Diagnostics revenue rose 17% to ₹178 crore, accounting for around 40% of the revenue mix.
Premium TruHealth packages grew by more than 50%, while radiology-integrated wellness packages expanded over 40%.
The growth in premium health packages reflects a broader consumer shift towards preventive healthcare, where customers increasingly opt for regular screenings and comprehensive health checks rather than only seeking diagnosis after illness.
Smaller cities emerge as growth engine
Metropolis saw particularly strong momentum in Tier III markets, where revenue increased around 25% during the quarter.
This was significantly higher than growth in:
- Tier I cities: 11%
- Tier II cities: 14%
The faster growth in smaller towns highlights the opportunity for organised diagnostic companies to expand beyond major urban centres, where healthcare awareness and access to branded services are improving.
Diagnostic chains are increasingly investing in collection centres, digital platforms and wider networks to tap demand from these markets.
Management highlights sustainable growth
Executive Chairperson Ameera Shah said the company delivered 17% revenue growth without any price increase, reflecting strong patient and clinician confidence in the Metropolis brand.
Managing Director Surendran Chemmenkotil said the quarterly performance reflected disciplined execution, with higher volumes and a 210-basis-point expansion in EBITDA margin demonstrating the scalability of the company’s operating model.
For diagnostic companies, improving margins while maintaining volume growth is a key indicator of business strength, as the sector benefits from economies of scale once laboratory infrastructure and networks are established.
Outlook
Metropolis’ June-quarter performance shows continued momentum across its core diagnostics business, with growth coming from both traditional testing services and newer wellness offerings.
The company’s ability to expand in smaller cities, increase digital engagement and grow premium diagnostics will remain important drivers as competition in the organised healthcare services sector increases.
At the same time, maintaining service quality and expanding its network efficiently will be crucial as diagnostic chains compete for a larger share of India’s growing healthcare market.
Also Read: BSE Q1 profit rises 10% to ₹874 crore; board approves increase in IIBH stake to 20%
